Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program


NEW YORK, April 24, 2019 /PRNewswire/ -- Emendo Biotherapeutics Inc today announced that the company signed a licensing option agreement with Takeda Pharmaceutical Company Limited. As part of the transaction, Emendo will receive an investment in convertible notes from Takeda Ventures, Inc., the corporate venture arm of Takeda. The funds will be used to further advance Emendo's novel nuclease gene editing discovery platform and proprietary product development programs.

The licensing option agreement grants Takeda the option to use OMNI, Emendo's proprietary nuclease program, to edit two genes as part of its research and development efforts. Further, Emendo will apply its novel gene editing engineering platform to optimize the OMNI nuclease to have the highest specificity and activity on Takeda's chosen genes.

"Extending our investment in Emendo and licensing its nuclease discovery platform and gene editing technology is another example of Takeda's commitment to investing in transformative advances in science via mutally advantageous partnerships," said Takeda Ventures Senior Partner Rob Woodman.

The notes will be converted in Emendo's planned B round financing intended to allow the company to advance its high precision gene editing biotherapies into initial clinical trials.  Emendo is moving several preclinical programs through optimization, in preparation for moving towards the clinic in a number of promising clinical indications. 

Emendo's gene editing program, OMNI, enables extremely specific gene editing which minimizes off target cuts and allows for highly focused therapeutic intervention in complex genetic diseases. 

Emendo's CEO, David Baram, says "We're pleased to be working with an innovative global pharmaceutical leader such as Takeda. This agreement further positions Emendo as a leading, next-generation, high-precision, gene editing company and promotes its allele specific editing programs that can potentially cure severe genetic disorders."

About Emendo

Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture arm of Takeda Pharmaceuticals Limited.

For more information:

David Baram, CEO
David@emendobio.com
+972-54-4907749


These press releases may also interest you

at 19:00
Innovative technology company, DOOGEE Hengtong Technology Co. Ltd., is today pleased to announce the launch of its latest phone, the DOOGEE S88 Pro. The DOOGEE S88 Pro is a rugged smartphone that is packed full of features including a 10,000 mAh...

at 17:00
Glenn Thomas, founder and principal of Pathway Capital Corporation, which specializes in funding solutions for complex transactions, announced that Robert Capalbo has joined his company's team of specialty finance professionals. A seasoned commercial...

at 13:00
Brander Group Inc. joins the strategic affiliate partnership program with INDATEL. Their group members part have relied on Brander Group to buy IP address blocks across the United States for the past few years. As local regional internet services...

at 11:00
Advanced Software Products Group (ASPG, Inc.) is pleased to announce the latest release of MegaCryption 6.5.0. Specifically designed for z/OS environments, MegaCryption is a comprehensive enterprise and mainframe cryptography toolkit providing...

at 08:30
AbbVie , a research-based global biopharmaceutical company, today announced new Phase 3 data from the SELECT-CHOICE clinical trial, showing that RINVOQtm (upadacitinib, 15 mg, once daily) met the primary endpoint of non-inferiority versus ORENCIA®...

at 06:45
Genetron Holdings Limited ("Genetron Health"), a China-based precision oncology company that covers full-cycle cancer care, announced that its independently developed detection kit for the novel coronavirus (Genetron SARS-CoV-2 RNA Test) received...



News published on 24 april 2019 at 04:00 and distributed by: